Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
Crit Rev Oncol Hematol ; 140: 17-27, 2019 Aug.
Article in English | MEDLINE | ID: mdl-31154235

ABSTRACT

Metastasis leads to poor prognosis and reduced disease-free survival in breast cancer patients, particularly in those with triple-negative breast cancer (TNBC) which is resistant to common treatments. Anoikis is a type of apoptosis commenced by the detachment of cells from the native extracellular matrix and prohibits the attachment of detached cells to other body organs. Resistance to anoikis is a critical culprit in the development and progression of tumours. It is therefore important to understand the anoikis-related molecular pathways in order to design effective therapies for TNBC. Several compounds have been shown to possess the potential to regulate anoikis in breast cancer cells such as DSF, AEB071, nanoencapsulated doxorubicin, berberine, salinomycin, PEM POL5551, AL10, 5-azacytidine, synthesized flavonoid derivative GL-V9, Tubeimoside V (TBMS-V) and HPW-RX40. We reviewed the molecular basis of anoikis regulation, its potential role as an important target to inhibit metastasis in TNBC, and potential anoikis modulators that could serve as drug candidates.


Subject(s)
Anoikis , Gene Expression Regulation, Neoplastic , Signal Transduction , Triple Negative Breast Neoplasms/physiopathology , Berberine/pharmacology , Berberine/therapeutic use , Chlorobenzoates/pharmacology , Chlorobenzoates/therapeutic use , Female , Humans , Pyrans/pharmacology , Pyrans/therapeutic use , Pyrroles/pharmacology , Pyrroles/therapeutic use , Quinazolines/pharmacology , Quinazolines/therapeutic use , Saponins/pharmacology , Saponins/therapeutic use , Styrenes/pharmacology , Styrenes/therapeutic use , Triple Negative Breast Neoplasms/drug therapy , Triple Negative Breast Neoplasms/genetics , Triple Negative Breast Neoplasms/metabolism
2.
N Engl J Med ; 369(4): 351-361, 2013 Jul 25.
Article in English | MEDLINE | ID: mdl-23883380

ABSTRACT

BACKGROUND: Pulmonary arterial hypertension is a devastating disease with high mortality. Familial cases of pulmonary arterial hypertension are usually characterized by autosomal dominant transmission with reduced penetrance, and some familial cases have unknown genetic causes. METHODS: We studied a family in which multiple members had pulmonary arterial hypertension without identifiable mutations in any of the genes known to be associated with the disease, including BMPR2, ALK1, ENG, SMAD9, and CAV1. Three family members were studied with whole-exome sequencing. Additional patients with familial or idiopathic pulmonary arterial hypertension were screened for the mutations in the gene that was identified on whole-exome sequencing. All variants were expressed in COS-7 cells, and channel function was studied by means of patch-clamp analysis. RESULTS: We identified a novel heterozygous missense variant c.608 G→A (G203D) in KCNK3 (the gene encoding potassium channel subfamily K, member 3) as a disease-causing candidate gene in the family. Five additional heterozygous missense variants in KCNK3 were independently identified in 92 unrelated patients with familial pulmonary arterial hypertension and 230 patients with idiopathic pulmonary arterial hypertension. We used in silico bioinformatic tools to predict that all six novel variants would be damaging. Electrophysiological studies of the channel indicated that all these missense mutations resulted in loss of function, and the reduction in the potassium-channel current was remedied by the application of the phospholipase inhibitor ONO-RS-082. CONCLUSIONS: Our study identified the association of a novel gene, KCNK3, with familial and idiopathic pulmonary arterial hypertension. Mutations in this gene produced reduced potassium-channel current, which was successfully remedied by pharmacologic manipulation. (Funded by the National Institutes of Health.)


Subject(s)
Channelopathies/genetics , Hypertension, Pulmonary/genetics , Mutation, Missense , Nerve Tissue Proteins/genetics , Potassium Channels, Tandem Pore Domain/genetics , Amino Acid Sequence , Channelopathies/drug therapy , Chlorobenzoates/therapeutic use , Cinnamates/therapeutic use , Exome , Familial Primary Pulmonary Hypertension , Female , Genetic Predisposition to Disease , Heterozygote , Humans , Hypertension, Pulmonary/drug therapy , Lung/pathology , Male , Molecular Sequence Data , Nerve Tissue Proteins/chemistry , Nerve Tissue Proteins/physiology , Pedigree , Potassium Channels, Tandem Pore Domain/chemistry , Potassium Channels, Tandem Pore Domain/physiology , Sequence Analysis, DNA , ortho-Aminobenzoates/therapeutic use
3.
Antimicrob Agents Chemother ; 9(2): 334-42, 1976 Feb.
Article in English | MEDLINE | ID: mdl-817659

ABSTRACT

The response of Pseudomonas aeruginosa to carbenicillin, BL-P1654, and two cephalosporins (112384 and 112883) was evaluated by minimal inhibitory concentration determinations, [(14)C]leucine uptake studies, morphological studies of colonial growth, and mouse intraperitoneal inoculations. Spheroplast formation and bacterial lysis were not the early response; instead, cell division was inhibited and long filaments were formed. Spheroplast formation and bacterial lysis were not observed in the first 7 h of incubation in minimal inhibitory concentrations of antibiotic.


Subject(s)
Carbenicillin/pharmacology , Cephalosporins/pharmacology , Penicillins/pharmacology , Pseudomonas aeruginosa/ultrastructure , Animals , Carbenicillin/therapeutic use , Cephalosporins/therapeutic use , Chlorobenzoates/pharmacology , Chlorobenzoates/therapeutic use , Guanidines/pharmacology , Guanidines/therapeutic use , Leucine/metabolism , Mice , Microbial Sensitivity Tests , Microscopy, Electron, Scanning , Penicillanic Acid/analogs & derivatives , Penicillins/therapeutic use , Pseudomonas Infections/drug therapy , Pseudomonas aeruginosa/drug effects , Pseudomonas aeruginosa/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...